Andrew Mignatti

Co-Founder and CEO

Andrew has spent the more than 15 years in the laboratory services business, focused primarily on molecular diagnostics.

With the launch of CoverMyTest, Andrew is bringing much-needed technological solutions in the independent laboratory field to further the best patient treatment and outcomes.

It is his belief that the rapidly growing molecular diagnostics and precision medicine areas are poised to overwhelm prior authorizations and more that affect the payors, LBMs and providers who lack such innovation.

Prior, Andrew was a member of the management team at RedPath Integrated Pathology, a molecular diagnostics laboratory focused on pancreatic cancer. Here, he had full P&L responsibility for the company. He also drove the sales and reimbursement strategy.

He focused much of his time and energy on cost reduction and improvements in lab efficiency. (RedPath was sold to PDI, which is now Interpace Diagnostic (nasdaq: IDX).

After the sale to PDI, Andrew became the CEO of Perthera, an information-based company focused on delivering the best treatment options for late-stage cancer patients. Here, he raised $10 million in funding for the company and more than doubled the revenue. Andrew took the company from a start-up to a successful operating business.

He began his career at Allergy Testing Laboratory, which was acquired by Esoterix, a conglomerate of specialty laboratories.

Andrew also has extensive sales experience, having started as an inside sales representative, then becoming a regional director of sales at Esoterix, which was sold to Laboratory Corporation of America (LabCorp).

At LabCorp, Andrew was a director of business development, responsible for acquisitions of physician offices and regional laboratories. He drove multiple office and laboratory acquisitions and integrations for the Midwest division, where he gained invaluable insight into the operating functions of a laboratory.